Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Expanded Access to Ensartinib for Participants With ALK+ NSCLC
Conditions:   Non-Small Cell Lung Cancer;   ALK Gene Rearrangement Positive
Intervention:   Drug: Ensartinib
Sponsor:   Xcovery Holding Company, LLC
Available

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 1, 2019 / by / in
Comments